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Abstract
Background: Optical molecular imaging is an emerging novel technology with applications in the diagnosis of
cancer and assistance in image-guided surgery. A high tumour-to-background (T/B) ratio is crucial for successful
imaging, which strongly depends on tumour-specific probes that rapidly accumulate in the tumour, while non-bound
probes are rapidly cleared. Here, using pre-invasive breast cancer as a model, we investigate whether the use of
combinations of probes with different target specificities results in higher T/B ratios and whether dual-spectral imaging
leads to improvements in tumour characterization.
Methods: We performed optical molecular imaging of an orthotopic breast cancer model mimicking ductal carcinoma
in situ (DCIS). A combination of carbonic anhydrase IX (CAIX)- and human epidermal growth factor receptor 2
(HER2)-specific variable domains of the heavy chain from heavy-chain antibodies (VHHs) was conjugated either
to the same fluorophore (IRDye800CW) to evaluate T/B ratios or to different fluorophores (IRDye800CW, IRDye680RD or
IRDye700DX) to analyse the expression of CAIX and HER2 simultaneously through dual-fluorescence detection. These
experiments were performed non-invasively in vivo, in a mimicked intra-operative setting, and ex vivo on tumour
sections.
Results: Application of the CAIX- and HER2-specific VHH combination resulted in an increase of the T/B ratio, as
compared to T/B ratios obtained from each of these single VHHs together with an irrelevant VHH. This dual tumour
marker-specific VHH combination also enabled the detection of small metastases in the lung. Furthermore, dual-spectral
imaging enabled the assessment of the expression status of both CAIX and HER2 in a mimicked intra-operative setting, as
well as on tumour sections, which was confirmed by immunohistochemistry.
Conclusions: These results establish the feasibility of the use of VHH ‘cocktails’ to increase T/B ratios and improve early
detection of heterogeneous tumours and the use of multispectral molecular imaging to facilitate the assessment of the
target expression status of tumours and metastases, both invasive or non-invasively.
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Background
Molecular imaging of cell surface markers has become
an increasingly important strategy for the imaging of
cancer, which may be used for diagnosis, for assessment
of therapy response and for guidance during surgical re-
section [1]. Optical molecular imaging has recently
attracted much attention, because the employed probes
are non-radioactive, and recent camera systems enable
high resolution imaging. One of the concerns raised by
optical molecular imaging is the limited sensitivity, due
to restricted light penetration into the tissue, which pre-
vents applications as whole-body imaging. Optical im-
aging is, however, perfectly suited for non-invasive
detection of superficial tumours (e.g. breast or head and
neck cancers) or tumours accessible using an endoscope
(e.g. lung cancer, tumours located in the gastrointestinal
tract or abdominal cavity). At the moment, under clin-
ical evaluation in several centres, the implementation of
optical molecular imaging into clinical practice could
complement current protocols and facilitate non-invasive
detection of cancer and monitorization of therapy re-
sponse (ClinicalTrials.gov; NCT02113202, NCT01972373,
NCT01508572, NCT02129933, NCT01987375). In
addition, it could allow accurate delineation of tumours
during surgery, for radical resections of tumours and their
neighbouring precursors with minimal removal of the sur-
rounding normal tissue. Moreover, optical molecular
imaging could likely advance current pathology through
ex vivo analysis of biopsies.
The basis of optical imaging lies in the detection of light
emitted from fluorophore, making it a cost-effective, non-
radioactive imaging modality for the detection of cancer,
both in the screening and intra-operative setting. Recent
advances in optical imaging probes are focused on the
development of near-infrared (NIR) fluorophores. Fluoro-
phores emitting light in the NIR range of the spectrum
(e.g. 700 and 800 nm) allow deeper tissue penetration than
the fluorophores which emit in the standard 400–600-nm
range. These advantages are a result of lower light absorp-
tion by blood and other tissue components, as well as of
minimal tissue autofluorescence in this range of the
spectrum [2–4].
Besides an appropriate NIR fluorophore and an im-
aging system able to detect the light emitted by this
fluorophore, optical molecular imaging requires high
tumour specificity, which can be obtained by employing
fluorescent probes targeting tumour-specific markers
that are ideally (over)expressed strictly in cancerous, and
not in normal, tissues. Several biomarkers have been
identified and their (over)expression has been associated
with cancer development. Among these are the human
epidermal growth factor receptor 2 (HER2) and the hyp-
oxia marker carbonic anhydrase IX (CAIX) [5, 6]. Vari-
ous targeting moieties have been employed to facilitate
tumour targeting, such as affibodies, peptides, conventional
monoclonal antibodies (mAbs) or antibody fragments. Pre-
viously, we reported successful optical molecular imaging
using the variable domain of the heavy chain from heavy-
chain antibodies (VHH, also referred to as nanobodies)
conjugated to the NIR fluorophore IRDye800CW in xeno-
graft mouse models [7, 8]. VHHs, which are the smallest,
naturally occurring, functional antigen binding fragments
of only 15 kDa, proved to be very promising tumour tar-
geting agents. Being a tenth of the molecular weight of
mAbs and having high binding affinity and specificity,
VHHs efficiently penetrate throughout the tumour mass
and are retained at the tumour. Due to the rapid accumu-
lation of these nanobodies into the tumour and their rapid
clearance (half-life of 1–2 h [8, 9]), its visualization is
already possible 2–4 h postinjection (p.i.). In contrast,
mAbs may require more than 24–48 h to accumulate at
the tumour and provide comparable contrast.
Sufficient signal (described as contrast or tumour-to-
background ratio, i.e. T/B ratio) and a clear delineation
of the tumour are essential for successful and accurate
tumour detection through imaging. Taking into account
the heterogeneity of cancers (e.g. breast cancers [10]), it
may be a challenge for a unique probe to provide
enough signal for optical imaging of early-stage cancers.
We hypothesized that the combination of two tumour-
specific probes could increase the T/B ratio and thus
facilitate tumour detection. Moreover, by using dual-
spectral imaging, information may be obtained about
expression levels of different tumour markers within
the same tumour, which could accelerate tumour
characterization.
In this study, we investigate whether a combination of
two optical probes that specifically recognize two inde-
pendent breast cancer markers could improve tumour
detection by optical imaging. For this, we have employed
the VHH B9 targeting CAIX, which localizes to peri-
necrotic regions of tumours [11], and the VHH 11A4
targeting HER2, which is known to have a more
homogenous distribution throughout the tumour tissue
[7]. These VHHs were selected based on their specificity
and binding affinity for their targets. B9 binds to CAIX
with an affinity of approximately 7 nM and it did not
bind to cells devoid of expression of CAIX nor to cells
expressing CAIX when in the presence of high concen-
trations of the CAIX ectodomain [11]. 11A4 binds to
HER2 with an affinity of approximately 500 pM, and its
specificity was demonstrated by the absence of binding
to the ectodomains of HER1, HER3 and HER4 and also
the absence of binding to cells that did not express
HER2 [7]. Subsequently, preclinical studies have shown
the rapid accumulation of these VHH probes in tumours
and have confirmed their specificity: 11A4 accumulated
in the SkBr3 HER2-positive subcutaneous tumour
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model, whereas no accumulation was observed in the
MDA-MB-231 HER2-negative model [7]. B9 accumulated
in a ductal carcinoma in situ (DCIS) orthotopic model, to
an extent that correlated with the expression level of
CAIX [11]. In the present study, both VHHs were conju-
gated to the same fluorophore, i.e. IRDye800CW, and the
T/B ratios after co-injection of both VHHs were com-
pared in a breast cancer tumour model with the T/B ratios
obtained after co-injection of either of the VHHs together
with an irrelevant VHH, R2. In addition, B9 and 11A4
were conjugated to different NIR fluorophores to investi-
gate whether this approach could be used to detect the ex-
pression status of CAIX and HER2 in vivo. This
combination of VHHs was also evaluated ex vivo in a
mimicked surgical context and for the detection of lung
metastases through dual-spectral optical imaging. Fi-
nally, immunohistochemistry was performed to validate
fluorescent 11A4 and B9 probe localization through
dual-spectral optical imaging of tumour sections. Our
data have revealed improved imaging by using a com-
bination of different nanobody-based optical probes.
Methods
Cell lines and cell culture conditions
MCF10DCIS.com (further referred to as MCF10DCIS)
cells (Asterand, Detroit, MI, USA), mimicking DCIS of
breast, were cultured according to the supplier’s guidelines
in Dulbecco’s modified Eagle medium nutrient mixture F-
12 (DMEM/F12) supplemented with 10 % (v/v) fetal calf
serum (FCS), 100 IU/ml penicillin, 100 μg/ml strepto-
mycin and 2 mM L-glutamine at 37 °C in a humidified
atmosphere containing 5 % CO2. The generation of lucif-
erase overexpressing MCF10DCIS cells has been de-
scribed before [12].
VHH production and purification
The HER2-specific VHH, 11A4, and the CAIX-specific
VHH, B9, were produced as described before [7, 11].
Briefly, VHH genes were re-cloned into the pQVQ72
expression vector (kindly provided by QVQ BV), which
enables site-directed conjugation of IRDye680RD malei-
mide and IRDye800CW maleimide (LI-COR Biosciences,
Lincoln, Nebraska, USA). Irrelevant VHH, R2, was pro-
duced as described previously [8]. Bacterial production
of the VHHs was induced by addition of 1 mM
isopropyl-beta-D-thiogalactopyranoside (IPTG) when
bacteria reached log phase. HER2- and CAIX-specific
VHHs were purified from the periplasmic fraction by
protein A affinity chromatography using a HiTrap protein
A HP column (GE Healthcare, Zeist, The Netherlands) on
the ÄKTAxpress system (GE Healthcare, Zeist, The
Netherlands). Irrelevant VHH (R2) was purified using
immobilized metal affinity chromatography (IMAC;
Talon; Takara Bio Europe/Clontech, Saint-Germain-en-
Laye, France).
Conjugation of the NIR fluorophores
Conjugation of the fluorophores was performed as de-
scribed before [7]. Briefly, 11A4 and B9 VHHs were
treated with 20 mM Tris(2-carboxyethyl)phosphine
(TCEP) in 50 mM Tris-HCl pH 8.5 for 15 min at room
temperature (RT), then the buffer was replaced to 0.4 mM
ethylenediaminetetraacetic acid (EDTA) in phosphate-
buffered saline (PBS, Lonza, Basel, Switzerland) using a
size-exclusion chromatography resin in Pierce Zeba™
Desalting Spin Columns (Thermo Fisher Scientific, Land-
smeer, The Netherlands) and incubated with a threefold
molar excess of fluorophore at 4 °C for 16 h. 11A4 was
either conjugated to IRDye680RD maleimide (further
referred to as 11A4-680) or to IRDye800CW maleimide
(further referred to as 11A4-800), while B9 was conjugated
exclusively to IRDye800CW maleimide (B9-800). The ir-
relevant VHH, R2, was randomly conjugated to N-hydro-
xysuccinimide (NHS) esters of either IRDye800CW or
IRDye700DX (referred to as R2-800 and R2-700, re-
spectively) in twofold molar excess of NIR fluorophore
to protein, for 2 h at RT. All fluorophores were pur-
chased at LI-COR Biosciences (Lincoln, Nebraska,
USA). After conjugation, the remaining unconjugated
fluorophores were removed using sequentially two (in
case of IRDye800CW) or three (in case of IRDye680RD
or IRDye700DX) Pierce Zeba™ Desalting Spin Columns
(Thermo Fisher Scientific, Landsmeer, The Netherlands).
The degree of conjugation was determined according to
the instructions given by the provider for each of the
fluorophores.
In vivo studies
Ethics statements: All procedures performed in studies
involving animals were in accordance with the ethical
standards and approved by the Animal Experimental
Committee of Utrecht University (DEC-Utrecht no.
2012.III.02.015).
The orthotopic mouse model of breast cancer
(MCF10DCIS cells) used in this study was based on a
previously described model [13]. In brief, SCID/Beige fe-
male mice (6 weeks old) were purchased from Harlan.
Animals were housed in standard Perspex cages with
free access to food and water. To reduce food-induced
fluorescence in the intestinal tract, animals received a
chlorophyll-free diet 2 weeks prior to imaging (Harlan
Laboratories, The Netherlands). In order to eliminate
autofluorescence by the fur, mice were shaved in the ab-
dominal and upper leg area and treated with Veet cream
(local pharmacy) to remove remaining hair. Forty thou-
sand MCF10DCIS cells were inoculated in the fourth
mammary glands at both sides of mice. After tumour
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formation (approximately 8–9 weeks after inoculation of
cells), mice carrying xenografts with diameters of ap-
proximately 0.5 cm were subjected to imaging.
In the first part of the study, where the advantage
of using two probes instead of one was tested with
respect to obtaining higher tumour-to-background ra-
tios (T/B ratios), mice were divided into three groups.
Each group was injected intravenously with one of
the following combinations of VHHs (50 μg of each
VHH-IR, thus 100 μg in total): 11A4-800 and B9-800
(n = 7), 11A4-800 and R2-800 (n = 7) or B9-800 and
R2-800 (n = 7). After the injections, mice were imaged
with the Pearl Impulse Small Animal Imaging System
(LI-COR Biosciences) at the following time points:
30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 24 h and 48 h
postinjection (p.i.). Regions of interest (ROIs) were
drawn in the tumour and in the upper leg region as
normal tissue areas. The upper leg region was chosen
as the background due to the proximity to the ab-
dominal area and the reduced risk for the mice, as
compared to the risk of shaving the thoracic breasts.
T/B ratios were calculated by dividing the mean
intensity of tumour ROI by the mean intensity of
background ROI (drawn in normal tissue area) deter-
mined with Pearl Impulse Software (v.2.0, LI-COR
Biosciences).
In the second part of the study, mice were divided into
three groups and then injected intravenously with com-
binations of VHHs conjugated to different NIR fluoro-
phores to study whether the expression status of HER2
and CAIX could be detected simultaneously in vivo
(50 μg of each VHH-IR, thus 100 μg in total): 11A4-680
and B9-800 (n = 8), 11A4-800 and R2-700 (n = 8) or B9-
800 and R2-700 (n = 7). After the injections, mice were
imaged as described above and the fluorescence inten-
sities of IRDye680RD and IRDye700DX were detected in
the 700-nm channel, whereas the fluorescence intensity
of IRDye800CW was detected in the 800-nm channel.
T/B ratios were calculated as described above.
In the third part of the study, the potential of VHH-IR
to detect lung metastasis was evaluated. For the develop-
ment of the lung metastasis model, 1 × 105 MCF10DCIS
cells were injected intravenously through the tail vein.
Having confirmed the presence of lung metastasis in a
non-invasive manner by bioluminescence imaging (Pho-
ton Imager, Biospace Labs, Paris, France), mice were
injected intravenously with the combination (50 μg of
each VHH-IR, 100 μg in total) of 11A4-680 and B9-800
(n = 3). As controls, one mouse was injected with R2-
800 and R2-700 and a healthy mouse with 11A4-680
and B9-800. Mice were sacrificed 5 h p.i. by cervical dis-
location, and lung metastases were imaged with the
Pearl Impulse Small Animal Imaging System (LI-COR
Biosciences) upon surgical removal of lungs.
Imaging of fluorescent sections and
immunohistochemistry
Mice injected with the combination of VHHs with either
IRDye800CW, IRDye680RD or IRDye700DX were sacri-
ficed 5 h p.i., and their tumours were collected. These
were first imaged (i.e. ex vivo) and, immediately thereafter,
fixed in neutral buffered formalin, routinely processed to
paraffin blocks and stored in the dark until further pro-
cessing. Four-micrometre-thick sections were scanned
using the Odyssey imaging system at the highest (21 μm)
resolution and quality. Immunohistochemistry (IHC) for
detection of CAIX and HER2 combined with a haema-
toxylin and eosin (H&E) staining were performed as
described before [10]. Slides were scanned with the Scan-
scope XT 120 scanner (Aperio, Vista, CA, USA).
Statistics
Statistical analysis was performed using GraphPad Prism
(version 5.02). Comparisons of T/B ratios were analysed
using a Mann-Whitney test. p values of <0.05 were con-
sidered to be statistically significant.
Results
Preparation of HER2- and CAIX-specific VHHs conjugated
to NIR fluorophores
In order to investigate whether a combination of two
fluorescent VHHs specifically recognizing two separate
and validated breast cancer biomarkers could (a) im-
prove tumour detection through optical imaging with an
increase in T/B ratio and/or (b) facilitate tumour
characterization and observation of different areas of the
tumour, we used the HER2-specific VHH, 11A4 [7], and
the CAIX-specific VHH, B9 [11]. Similarly to our previ-
ous studies [7, 11], in order to prevent any effect of the
fluorophore conjugation on the binding affinity, both
VHHs were site-specifically conjugated to their respect-
ive fluorophores using a cysteine that was introduced in
the C-terminal region. Besides this extra cysteine, most
VHHs possess two cysteines that form a disulfide bridge,
which is inside the structure of the folded protein, and
contributes to protein integrity. In this study, 11A4 was
site-specifically conjugated to either maleimide
IRDye800CW or IRDye680RD (named 11A4-800 and
11A4-680, respectively), whereas B9 was conjugated to
IRDye800CW only (named B9-800). In all in vivo experi-
ments, we have included an irrelevant VHH, R2, as a
control. As the binding affinity of this control VHH is of
less importance, R2 was randomly conjugated to either
IRDye800CW or IRDye700DX (referred to as R2-800
and R2-700, respectively). After purification of the fluor-
escent conjugates, the amount of free fluorophore
remaining in the sample was less than 5 % of the total
fluorophore and thus these conjugates were considered
suitable for use in the in vivo study (determined by
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sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE), Additional file 1: Figure S1). The
degree of conjugation of each of the fluorophores to
each VHH was 0.5, which is in agreement with previ-
ously reported data [7, 8].
In vivo single-spectrum imaging using a combination of
VHHs
To investigate whether the targeting of the tumour with
two tumour-specific VHHs conjugated to the same
fluorophore results in an increased contrast, we injected
intravenously seven mice bearing two MCF10DCIS
breast cancer xenografts in the fourth mammary glands
with either 11A4-800 and B9-800 or the controls 11A4-
800 and R2-800 or B9-800 and R2-800. The imaging was
performed up to 48 h postinjection (p.i.). Already 3 h
p.i., a clear accumulation of the fluorescent probes was
seen in the tumours for each of the three probe combi-
nations (Fig. 1a, red arrows). NIR fluorescence was also
found at the bladder, which is expected due to the rapid
renal clearance of the VHH. Accumulation of the NIR
fluorescence at the kidneys was not visible, because mice
were imaged ventrally. Fluorescence intensities were
determined for each individual tumour (two tumours
per mouse of seven mice in total) and a non-tumour tis-
sue in the leg area, in such a way that the signal was not
affected by the signal of the tumour or bladder (i.e. back-
ground). The T/B ratios were calculated and plotted in
time (Fig. 1b). Over time, the background fluorescence
decreased as a result of rapid clearance of the probes,
which led to an increase in contrast expressed as T/B ra-
tios. After combining T/B ratios obtained at all time
points, an overall significant difference in T/B ratio
increase was found between the group injected with
11A4-800 and B9-800 and the control groups injected
with either 11A4-800 and R2-800 (22 % increase in T/B
ratio) or the B9-800 and R2-800 cocktail (51 % increase
in T/B ratio) (Fig. 1b). Interestingly, we also observed a
significant difference between the two control groups,
which indicated that the signal obtained with the HER2-
specific VHH was higher than that obtained with the
CAIX-specific VHH.
In vivo dual-spectral imaging using a combination of
VHHs
To determine whether two independent VHHs conju-
gated to two different NIR fluorophores have the poten-
tial to determine the expression levels of two relevant
breast cancer markers in vivo, mice were injected intra-
venously with B9-800 and 11A4-680 or with the controls
B9-800 and R2-700 and 11A4-680 and R2-700. As
expected, tumour xenografts were visible already 2 h p.i.;
however, the background fluorescence was also high at
that time point (Fig. 2a–c) probably due to incomplete
clearance of non-bound fluorescent VHHs. Clear delinea-
tion of the tumours was possible 4 h p.i. The irrelevant
VHH, R2-700, was also found at the tumour site, but this
occurred to a lesser extent as compared to the tumour-
specific fluorescent VHHs (Fig. 2b, c). Both 11A4-800 and
B9-800 specifically accumulated at the tumour when co-
injected with irrelevant VHH, in a similar manner to the
co-injection of these tumour-specific VHHs (Fig. 2).
The T/B ratios were calculated and plotted in time,
revealing that the maximal T/B ratios were obtained
already 2 h p.i. (Fig. 3). The T/B ratios of the irrele-
vant VHH, R2-700, were close to 1 (the average T/B
ratio was equal to 1.56 ± 0.41) and showed no in-
crease in time, suggesting no specific accumulation of
the irrelevant VHH at the tumour. To enable suffi-
cient removal of non-bound fluorescent VHH and
therefore decrease of background intensity levels, 6 h
p.i. was selected as an optimal imaging time point. A
significant difference between the 11A4-680 and B9-
800 T/B ratios was obtained 6 h p.i. (Fig. 3a; p =
0.0438). Significant differences were also observed be-
tween 11A4-800 and the irrelevant VHH, R2-700
(Fig. 3b; p = 0.0001). The difference between B9-800
and the irrelevant VHH, R2-700, at 6 h p.i. was of
borderline significance (Fig. 3c; p = 0.0582).
Dual-spectral imaging in the mimicked surgical setting
To investigate the possible application of dual-spectral
imaging in the surgical setting, a number of mice bear-
ing MCF10DCIS xenografts were injected with the indi-
cated fluorescent VHH combinations, and 5 h p.i. mice
were sacrificed, the skin was removed thereby uncover-
ing the xenografts and optical imaging was performed
(Fig. 4a). The following VHH combinations were
injected: B9-800 and 11A4-680, B9-800 and R2-700, and
11A4-800 and R2-700. As expected, a clear accumula-
tion of IR fluorescence was found at the tumour site, for
the HER2- and CAIX-specific probes. T/B ratios of
11A4-680 were approximately 73 % higher than T/B
ratios determined upon injection of B9-800 (Fig. 4b).
The T/B ratios of tumour marker-specific VHHs, i.e.
11A4-800 and B9-800, were approximately twofolds
higher than those of the irrelevant VHH.
Compared to the results obtained with in vivo imaging
(Fig. 3), the T/B ratios obtained after imaging tumours
in this mimicked invasive manner were approximately
twofolds higher at each time point p.i. for the 11A4 and
B9 VHHs, whereas no differences in T/B ratios were
observed in the case of the control R2-700 analysed in
these two manners.
Dual-spectral imaging of lung metastases ex vivo
MCF10DCIS cells are known to have the capacity to
metastasize into the lungs. In this part of the study, the
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VHH combination B9-800 and 11A4-680 was evaluated
for its potential to detect metastasis in the surgical set-
ting. This could provide valuable information on their
tumour marker expression status and its molecular
resemblance to the primary tumour. When metastases
of 1–2 mm were detected through BLI, mice were
injected with the B9-800 and 11A4-680 combination. As
controls, one mouse with developed lung metastases was
injected with R2-800 and R2-700 irrelevant VHH com-
bination and a healthy mouse without metastases was
injected with B9-800 and 11A4-680 combination. Five
hours p.i., all mice were sacrificed and their chest wall
was removed in order to facilitate the imaging of the
lungs. No NIR fluorescence was found in the healthy
lung controls, thus confirming the tumour marker speci-
ficity of both B9-800 and 11A4-680. A clear fluorescent
signal was observed at the lung bearing metastasis when
the mouse was injected with the B9-800 and 11A4-680
VHH combination, which was twice the intensity of the
R2-800 and R2-700 irrelevant VHH combination (Fig. 5).
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Fig. 1 Use of a combination of two tumour-specific VHHs for optical imaging results in higher T/B ratios. a Optical imaging of mice xenografted
with MCF10DCIS cells in time upon injection of the combination 11A4-800 and B9-800 (upper panel) and the control combinations, 11A4-800 and
R2-800 (middle panel) or B9-800 and R2-800 (bottom panel). Arrows point to tumours, bl depicts bladder. b T/B ratios in time (n = 7 per group).
Graph represents mean ± SEM. These were calculated from ROIs drawn around each tumour and non-tumour area. c Comparison of overall T/B
ratios and their SEM obtained at all time points for animals injected with B9-800 and 11A4-800 and the controls: B9-800 and R2-800 or 11A4-800
and R2-800. The p values were determined, and statistical significance is indicated by * when p < 0.05, ** when p < 0.01 and *** when p < 0.0001
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Dual-spectral imaging of tumour sections and
immunohistochemical validation
To investigate the possibility of the ex vivo assessment
of the molecular status of the tumour by employing the
11A4-680 and B9-800 combination, dual-spectral





























Fig. 2 Dual spectral molecular imaging using tumour-specific VHHs
allows for simultaneous expression status determination of two
different tumour markers, namely CAIX (targeted by VHH B9) and
HER2 (targeted by VHH 11A4). Irrelevant VHH R2-700 was used as
a negative control. Mice xenografted with MCF10DCIS cells were
imaged in time upon injection of the following: a tumour-specific
combination consisting of 11A4-680 and B9-800, b control combination
consisting of 11A4-800 and R2-700 and c control combination consisting
of B9-800 and R2-700. The observed yellow colour present in the overlays













































Fig. 3 Rapid increase of T/B ratio in the first 6 h p.i. allows fast imaging
upon injection of the following: a B9-800 and 11A4-680 (n= 8), b 11A4-
800 and R2-700 (n= 8) and c B9-800 and R2-700 (n= 7). Graphs represent
mean ± SEM. At 6 h p.i, the p values were determined and statistical
significance is indicated by * when p < 0.05 and *** when p < 0.0001

































































Fig. 4 Dual-spectral imaging with two tumour-specific VHHs allows simultaneous tumour molecular status determination in an invasive, mimicked
intra-operative setting. a Five hours p.i. of 11A4-680 and B9-800 (left), 11A4-800 and R2-700 (middle) or B9-800 and R2-700 (right) mice were sacrificed
by cervical dislocation and their skin removed to mimic image-guided surgery setting. b–d T/B ratios were calculated for tumours imaged
in the mimicked intra-operative setting. Bars represent mean, n = 4 mice in groups 11A4-800 and R2-700 and B9-800 and 11A4-680, n = 6
mice in group B9-800 and R2-700. Statistical significance is indicated by * when p < 0.05 and *** when p < 0.0001
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imaging of tumour sections was conducted and com-
pared to conventional haematoxylin and eosin (H&E)
staining. The HER2-targeted probe, 11A4-680, was ob-
served to be homogenously distributed throughout the
tumour section, while the CAIX-targeted one, B9-800,
was only confined to the peri-necrotic areas of the
tumour (Fig. 6a, asterisks (*) showing necrotic areas).
Tumour sections obtained from mice that were injected
with control combinations, B9-800 and R2-700, and
11A4-800 and R2-700, only presented NIR fluorescence
signal in the 800-nm channel. The distribution pattern
of B9-800 and 11A4-800 from these control combina-
tions was similar to the one observed for the 11A4-680
and B9-800 combination (Fig. 6b, c, respectively). These
results confirm the specific uptake of both HER2- and
CAIX-targeted VHHs. In parallel, IHC analysis of the
tumour sections confirmed HER2 expression of the tu-
mours by a 2+ HER2 DAKO score for expression which
was homogenously distributed throughout the tumour
section, while CAIX expression was confined to the
peri-necrotic tumour areas (Fig. 6d). These results valid-
ate the specificity of these VHHs for dual-spectrum im-
aging on tumour tissue sections.
Discussion
Despite many efforts made over the years to facilitate can-
cer detection, improvements are still eagerly awaited. At
the moment, six imaging modalities can be used to detect
and stage cancer, namely the following: x-ray (computed
tomography, CT), magnetic resonance imaging (MRI),
single-photon emission tomography (SPECT), positron
emission tomography (PET), ultrasound (US) and, more
recently, clinical evaluation initiated with optical imaging.
Each of these techniques has advantages but also limita-
tions. Recent advances in targeted probe development
stimulated further improvements of PET, SPECT and
more recently also of optical imaging [14, 15]. Although
the advantages of optical imaging are clear (e.g. no ioniz-
ing radiation thus no need of protection for personnel; no
radioactive decay of probe thus longer stability), the sensi-
tivity of this technique is still a concern, especially as a
result of the limited penetration of light into tissues, which
restricts its application to non-invasive detection of super-
ficial tumours (or tumours accessible using an endoscope),
image-guided surgery or fluorescence imaging of tissue
sections. We have previously demonstrated that VHHs
provide better T/B ratios than conventional antibodies at
B9-800 11A4-680 merge photograph
R2-800 R2-700 merge 
lung metastases

















Fig. 5 Optical molecular imaging with two tumour-specific VHHs allows detection of lung metastasis ex vivo. Optical imaging of metastasized
lungs 5 h p.i. of B9-800 and 11A4-680 combination (upper panel) or the control R2-800 and R2-700 (middle panel). Optical imaging of healthy lungs 5 h
p.i. of B9-800 and 11A4-680 (lower panel). Yellow colour in the overlay panel corresponds to the overlay of green (B9-800) and red (11A4-680) colours
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earlier time points p.i. [7, 8]. As a result of their
small size, VHHs accumulate more rapidly in the
tumour, and the non-bound fraction is more rapidly
cleared. In fact, very recently, the first report was
published on a phase I clinical trial of a VHH target-
ing HER2 for assessment of HER2 expression in
breast cancers through PET [16]. The encouraging re-
sults obtained warrant further evaluation in a phase II
trial and highlight the potential of the VHHs as
probes, also for whole-body imaging when combined
with different imaging modalities.
Taking into account the heterogeneity of (pre-invasive)
breast cancers [10] as a model, here, we investigated
whether the combination of two fluorescent VHHs tar-
geting two independent and validated tumour markers
could improve tumour detection through optical im-
aging by an increase in T/B ratios. The employed VHH
combination consisted of a VHH binding to HER2 and a
VHH binding to CAIX. The performance of this com-
bination was evaluated in an orthotopic tumour model
mimicking the comedo subtype of DCIS, which, as we
described earlier [12], is associated with a relatively high
risk of local recurrence and progression to invasive can-
cer. Crucial for these studies is the similar conjugation
efficiency of the fluorophore to the two VHHs. This
could allow comparison between the different groups
based on the fluorescence intensity measured. To avoid
any detrimental effects of fluorophore conjugation on
the binding capacity of the VHH, we performed the con-
jugation using maleimide-modified fluorophores that
bind directly to the C-terminal cysteine at the VHH.
Our data nicely show that the injection of two tumour-
specific VHHs that carry the same NIR fluorophore
results in a higher T/B ratio than the injection of a sin-
gle tumour-specific VHH combined with an irrelevant
VHH. This resulted in a clear tumour delineation at
early time points p.i. Interestingly, significant differences
in T/B ratios were also obtained between the control
groups, indicating that HER2-targeted VHH injections
result in a higher T/B ratio than imaging with CAIX-
targeted VHH. This result may be explained by the dif-
ferences in expression level of the different targeted
molecules. In fact, immunohistochemical analysis of
HER2 expression showed that it is homogenously dis-
tributed throughout the tumours, in contrast to CAIX
whose presence was limited to the peri-necrotic region
[17]. This result suggests that the application of more than
one tumour marker-specific VHHs could overcome intra-
*
1 mm
B9-800                    11A4-680                merge                     H&E       a
HER2-IHC                           H&E                                         CAIX-IHC
*
1 mm
0.5 mm             16x 0.5 mm            0.5 mm           16x
*
1 mm
 11A4-800                R2-700                    merge                                      H&E   
B9-800                    R2-700                    merge                                     H&E     b
d
c
Fig. 6 Dual-spectral fluorescence molecular pathology allows simultaneous determination of HER2 and CAIX expression status. Detection of
fluorescence on tumour sections obtained from mice 5 h p.i. of the combinations a 11A4-680 and B9-800, b 11A4-800 and R2-700 and c B9-800
and R2-700. The fluorescence detected with the odyssey scanner is depicted in green for channel 800 nm (IRDye800CW) and in red for channel
700 nm (IRDye680RD and IRDye700DX). H&E staining of the corresponding section is depicted, where an asterisk indicates necrotic area. d IHC on
sections of tumour xenografts depicting expression of HER2 and CAIX
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tumoural heterogeneity and improve T/B ratios even fur-
ther. The small size of the VHHs is particularly important
for this application as it allows simultaneous binding of
different VHHs to neighbouring molecules, most likely
without steric hindrance. For translational purposes, the
number of combined VHH probes may be limited by the
maximum dose possible to administer for imaging pur-
poses, and the clinical testing may be prolonged by the
need for single-probe testing prior to the cocktail testing
in patients. Thus, considering the path each single
imaging probe should follow before it is approved for
first-in-human testing, it may be relevant to consider the
investigation of bispecific VHHs, i.e. two independent
VHHs fused in one molecule. Important for this will be to
determine whether a bispecific VHH can distribute
throughout tissues as well as the combination has shown
to distribute in these studies. In addition, non-competitive
VHHs targeting the same tumour marker could be com-
bined as simultaneous binding of different VHHs to the
same target molecule would likely lead to even better T/B
ratios and consequently to an improved tumour detection.
The current diagnostic ‘gold standard’ in biomarkers’
expression assessment relies exclusively on ex vivo
methods, such as immunohistochemistry (IHC) and gene
amplification-based fluorescent in situ hybridization
(FISH). To obtain tissue for these assessments, a biopsy is
required. This invasive procedure may have side effects,
such as bleeding, and it is difficult to take many biopsies
or repeat the procedure for monitoring the treatment re-
sponse [18]. Furthermore, taking biopsies from metastases
to assess receptor profiles is now common but is an even
greater burden to the patient as many sites are not easily
accessible [19]. Due to these limitations, non-invasive
alternatives would be preferred to the current protocols.
In this context, we have also investigated the potential of
using two probes, targeting two independent and validated
tumour markers with two distinct fluorophores, to facili-
tate tumour characterization and observation of different
areas of the tumour. This proof of principle study demon-
strates that in vivo dual-spectral imaging of two independ-
ent tumour markers, namely CAIX and HER2, is feasible.
An important implication of this result is that it enables the
simultaneous determination of the expression status of two
tumour markers, both in a non-invasive manner in vivo, as
well as ex vivo. Here, the choice of NIR fluorophore to con-
jugate to each VHH was carefully made, based on the
requirements of each VHH (e.g. site-directed conjugation)
and the available fluorophores that are compatible with the
imaging system employed. Importantly, the fluorescence of
the selected fluorophores was detected by the independent
channels, without interferences (Additional file 2). Interest-
ingly, we have observed that the T/B ratios differed by a
factor of 2 in the case of 11A4-680 and 11A4-800 (Figs. 3
and 4). This can be explained by a difference in background
fluorescence levels (Additional file 1: Figure S2), which were
slightly higher in the case of 11A4-800 (726 ± 138 vs 395 ±
120). The reason for this is not clear; however, it seems to
be related to differences in distribution and clearance of the
IRDye800CW, compared to the IRDye680RD.
To our knowledge, this is the first study in which VHHs
were used in a dual-spectral imaging setting. The idea of
imaging with a combination of probes has been earlier
investigated by Barrett et al. with the use of mAbs targeting
epidermal growth factor receptor (EGFR) and HER2 conju-
gated to NIR fluorescent dyes such as Rhodamine green,
Cy5.5 or Cy7 [20]. The tumour delineation was possible
only 24 h p.i. of the mAb combination. Koyama et al. pre-
sented a study in which optical imaging was performed
with three different mAbs, namely cetuximab (anti-EGFR),
trastuzumab (anti-HER2) and daclizumab (anti-IL-2Rα),
conjugated to three different fluorophores. Also in their
study, optimal T/B ratios were obtained only 24 h p.i. [21].
Similar results were obtained by Sano et al. [22]. Xie et al.
compared four different NIR fluorescent probes in a sub-
cutaneous xenograft mouse model 24 h p.i. to biolumines-
cent and IHC data concluding that optical molecular
imaging is a feasible approach to enable the detection of
different tumour features simultaneously [23]. In these
studies, optimal imaging conditions were obtained not earl-
ier than 24 h p.i. Importantly, our data show that VHHs
offer sufficient target specificity enabling dual-spectral im-
aging providing optimal contrast for tumour detection
already 2–4 h after injection.
Crucial for image-guided surgery is the clear delineation
of the tumour and determination of the margins. As could
be expected, after removal of the skin from the fourth
mammary glands, higher T/B ratios were obtained as
compared to T/B ratios obtained in a non-invasive im-
aging setting. These observations highlight the potential of
dual- or even multispectral imaging in the surgical setting,
allowing for complete tumour visualization in order to
enable radical tumour resections. However, at wavelengths
shorter than 800 nm, more autofluorescence can be
expected. It is therefore essential that the development of
probes suitable for dual- or even multispectral imaging is
followed by improvement in imaging systems that would
provide imaging with accurate separation of each signal.
Similarly to many other cancers that can evolve into
metastatic disease, breast cancer is a clinically heteroge-
neous disease, which develops distant metastasis in 10–
15 % of breast cancer patients during 3 years postdetection
of the primary tumour [24]. Based on autopsy data, the
most common sites for metastatic spread are the bone, lung
and liver [24–26]. With the proof of principle dual-spectral
analysis of the MCF10DCIS lung metastasis model, we
could detect small metastases in the millimetre range. We
expect that the simultaneous targeting of several different
tumour markers might further improve the detection of
Kijanka et al. EJNMMI Research  (2016) 6:14 Page 11 of 13
small metastases, which could have a great importance in
the surgical setting. For whole-body imaging and initial de-
tection of metastases, VHHs could possibly be employed
with nuclear imaging, as suggested recently by Keyaerts
and co-workers [16]. Metastases may differ in the expres-
sion of tumour markers compared to the primary tumour
[19]; therefore, this approach could increase the probability
of detecting the metastases in a surgical setting and in
addition provide the information of which tumour markers
are predominant. In such a setting, a general ‘cocktail’ of
different tumour markers—the most frequently present
markers in all breast cancers—could be sufficient to detect
most, if not all, cancerous lesions. The use of different
fluorophores in such a ‘cocktail’ could provide further infor-
mation on the molecular heterogeneity of the tumours. In
relation to this, we recently performed a study to determine
which tumour markers would be sufficient to image most
of breast cancers. The combination of HER2, CAIX,
GLUT1, EGFR, IGF1-R and MET could detect 45.5 % of
tumours, including basal/triple negative and HER2-driven
ductal cancer [10]. The addition of markers with a twofold
T/B ratio could increase the detection rate to 98 % [10].
Furthermore, multispectral optical imaging is a step for-
ward towards implementation in the clinic of the recently
introduced concept of molecular fluorescence pathology,
as a cost-effective, time-efficient and sensitive technique,
complementary to conventional IHC. Direct fluorescence
imaging of the VHHs conjugated to NIR fluorophores
already present in the tumour tissue would require no fur-
ther costly lab processing, but only sectioning of the tissue
blocks and subsequent imaging. This molecular fluores-
cent pathology would, however, strongly depend on the
imaging target and probably be restricted to cell surface
markers that are accessible to VHHs.
Conclusions
With this feasibility study, we show the successful op-
tical molecular imaging of CAIX- and HER2-positive
DCIS xenografts employing a combination of two
tumour-specific VHHs, in vivo, in the mimicked surgi-
cal setting, as well as ex vivo on tumour sections. The
simultaneous determination of the expression status of
multiple, clinically relevant tumour markers could lead
to a better detection of the primary tumour and its
metastases, providing optimal tumour delineation dur-
ing surgery under image guidance. Furthermore, this
approach could provide a more rapid assessment of
tumour marker expression in the pathological setting.
Altogether, although this is a proof of principle study
and further studies are certainly needed to assess the
potential of this approach in the clinic, multispectral
optical imaging could possibly improve the current
management of patients from early diagnosis of cancer
to surgical procedures, treatment decision-making and
monitoring of treatment response.
Additional files
Additional file 1: Supplementary methods and figures. Figure 1S:
SDS-PAGE analysis of NIR fluorescent VHHs. Figure 2S: Total fluorescence
intensity of 11A4-800 and 11A4-680 at the tumour and in the background
area obtained 5 h p.i. during the ex vivo tumour imaging. (34.9 MB)
Additional file 2: Signal bleeding. Each fluorescent VHH is detected by
one channel only of the imaging system. (4.16 MB)
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